|Articles|May 19, 2010
- Psychiatric Times Vol 27 No 5
- Volume 27
- Issue 5
Get the Bigger Therapeutic Picture
Advertisement
- Cochrane Central Register of Controlled Trials (CENTRAL) is a bibliographical database of controlled trials. This is an important resource because using MEDLINE alone will not yield all possible reports of controlled trials.
http://uscc.cochrane.org/en/newPage3.html . Accessed March 24, 2010.
- MedWatch is the FDA safety information and adverse reporting program.
http://www.fda.gov/safety/MedWatch/default.htm . Accessed March 24, 2010.
- The Carlat Psychiatry Report is a monthly newsletter that provides clinically relevant, unbiased information on psychiatric practice and psychotropic medications and openly discusses alternatives to psychopharmacological treatment.
http://www.thecarlatreport.com . Accessed March 24, 2010.
- PharmedOut is a physician-run project funded through the Attorney General Consumer and Prescriber Education grant program that “empowers physicians to identify and counter inappropriate pharmaceutical promotion practices. PharmedOut promotes evidence-based medicine by providing news, resources, and links to pharma-free CME courses.”
http://www.pharmedout.org . Accessed March 24, 2010.
Articles in this issue
about 16 years ago
Ethical Aspects of Self-Disclosure in Psychotherapyabout 16 years ago
Introduction: Ethical Dilemmas Old and Newabout 16 years ago
Undue Pharmaceutical Influence on Psychiatric Practiceover 16 years ago
A Psychiatrist’s Guitar Poemover 16 years ago
DSM5 and the Medicalization of Grief: Two Perspectivesover 16 years ago
Extraordinarily Ordinaryover 16 years ago
The Political Diagnosis: Psychiatry in the Service of the Lawover 16 years ago
The Fort Hood Aftermath-Army Accountability Review and Psychiatristsover 16 years ago
Memory Reconsolidation and What Albert Ellis Knew All AlongAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
Brain Trust: Carl Salzman, MD, on Benzodiazepine Mindful Prescribing, Misuse, and Dependence
2
Phase 4 Trial of Viloxazine ER Shows Real-World Gains for ADHD With Comorbid Depression, Anxiety
3
Experience With Xanomeline/Trospium in an Acute Inpatient Setting Treating Individuals With Schizophrenia
4
DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial
5